keyword
MENU ▼
Read by QxMD icon Read
search

Natalizumab

keyword
https://www.readbyqxmd.com/read/29143589/biomarkers-in-the-evolution-of-multiple-sclerosis
#1
Thomas Berger
Nonimaging biomarkers can be applied in differential diagnosis, evaluation of disease progression and therapy monitoring of multiple sclerosis (MS). Presence of oligoclonal IgG bands in cerebrospinal fluid is a diagnostic element and a negative predictor of MS evolution. AQP4 antibodies are pathogenic and diagnostic for neuromyelitis optica spectrum disorder. Antibodies to myelin oligodendrocyte glycoprotein develop in about 50% of predominantly pediatric patients with acute disseminated encephalomyelitis, but their possible role in pathogenesis is unknown...
November 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29142146/inflammatory-natalizumab-associated-pml-baseline-characteristics-lesion-evolution-and-relation-with-pml-iris
#2
Mike P Wattjes, Martijn T Wijburg, Jeroen van Eijk, Stephan Frequin, Bernard M J Uitdehaag, Frederik Barkhof, Clemens Warnke, Joep Killestein
BACKGROUND AND OBJECTIVE: Natalizumab-associated progressive multifocal leukoencephalopathy (NTZ-PML) patients may show imaging signs suggestive of inflammation at diagnosis ('inflammatory PML'), reminiscent of PML-immune reconstitution inflammatory syndrome (PML-IRIS). We investigated the imaging characteristics of inflammatory NTZ-PML lesions and PML-IRIS to determine differentiating and overlapping features. METHODS: We scored the presence, localisation and pattern of imaging characteristics of inflammation on brain MRI scans of inflammatory NTZ-PML patients...
November 15, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29141809/treatment-satisfaction-across-injectable-infusion-and-oral-disease-modifying-therapies-for-multiple-sclerosis
#3
Tessa Eagle, Fiona Stuart, Alicia S Chua, Allison LaRussa, Kaitlynne Leclaire, Sandra L Cook, Tanuja Chitnis, Howard L Weiner, Bonnie I Glanz, Brian C Healy
BACKGROUND: The recent approval of oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) has provided patients with a new route of therapy administration. Little research has compared patients' experiences with and perceptions of injectable, infusion and oral MS therapies. METHODS: Three hundred fifty-seven treated MS patients enrolled in the CLIMB study completed the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM provides information regarding perceived effectiveness, side effects, convenience and overall satisfaction...
November 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29138683/the-evaluation-of-oxidative-stress-parameters-in-serum-patients-with-relapsing-remitting-multiple-sclerosis-treated-with-ii-line-immunomodulatory-therapy
#4
Bożena Adamczyk, Sławomir Wawrzyniak, Sławomir Kasperczyk, Monika Adamczyk-Sowa
Objectives: The assessment of oxidative stress (OS) in serum relapsing-remitting multiple sclerosis patients treated with II-line immunomodulatory therapy (fingolimod, natalizumab) compared to newly diagnosed patients (de novo group) treated with interferon (IFN) beta and controls. The relationship between OS parameters and gender, age, disease duration, Expanded Disability Status Scale, annualized relapse rate, MRI lesions in patients treated with II-line. Materials and Methods: One hundred and twenty-one patients with RRMS were enrolled in the study...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/29119538/safety-and-effectiveness-of-natalizumab-first-report-of-interim-results-of-post-marketing-surveillance-in-japan
#5
Takahiko Saida, Kazumasa Yokoyama, Ryusuke Sato, Haruki Makioka, Yukihiko Iizuka, Masakazu Hase, Yan Ling, Shinichi Torii
INTRODUCTION: Natalizumab, a humanized anti-α4 integrin monoclonal antibody, received marketing approval in Japan in 2014 for the treatment of multiple sclerosis (MS). Because the previous large-scale clinical trials of natalizumab were mainly conducted in Europe and North American countries, and data in patients with MS from Japan were limited, we conducted an all-case post-marketing surveillance of natalizumab-treated MS patients from Japan to investigate the safety and effectiveness of natalizumab in a real-world clinical setting in Japan...
November 8, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/29116601/abnormal-cervical-lymph-nodes-in-multiple-sclerosis-a-preliminary-ultrasound-study
#6
Francesca Di Giuliano, Maria Albanese, Eliseo Picchi, Francesco Mori, Fabio Buttari, Girolama Alessandra Marfia, Francesco Garaci, Nicola Biagio Mercuri, Roberto Floris, Diego Centonze, Simone Marziali
BACKGROUND: Cervical lymph nodes are the first drainage stations of the brain and therefore play a key role in neuroinflammatory disorders such as multiple sclerosis. OBJECTIVE: The aim of this study was to evaluate, by using ultrasound imaging, cervical lymph nodes in patients with multiple sclerosis and to ascertain if such patients have any clinical features to attest their role. METHODS: We enrolled 43 patients affected by relapsing-remitting multiple sclerosis (22 drug free and 21 under treatment with natalizumab or fingolimod), who underwent ultrasound examination...
November 7, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/29111011/improvement-of-quality-of-life-and-its-relationship-with-neuropsychiatric-outcomes-in-patients-with-multiple-sclerosis-starting-treatment-with-natalizumab-a-3-year-follow-up-multicentric-study
#7
Vincent Planche, Xavier Moisset, Remy Morello, Emilie Dumont, Marion Gibelin, Julie Charré-Morin, Aurore Saubusse, Audrey Mondou, Françoise Reuter, Gilles Defer, Jean Pelletier, Bruno Brochet, Pierre Clavelou
BACKGROUND: Health-related quality of life (HRQoL) is impaired in multiple sclerosis (MS) but can be improved by disease-modifying therapies such as natalizumab. However, the predictive factors and neuropsychiatric correlates of HRQoL improvement are unknown. METHODS: In this study, 48 patients with relapsing-remitting MS were included in a 3-year open-label, single group, multicenter, clinical trial (NCT01392872). HRQoL was measured by the disease-specific MusiQoL questionnaire, together with physical disability, cognition, fatigue, anxiety and depression scores at baseline, 6months, 12months, 18months and 36months after starting natalizumab therapy...
November 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29110882/substantial-disease-exacerbation-in-a-patient-with-relapsing-remitting-multiple-sclerosis-after-withdrawal-from-siponimod
#8
Tomasz Litwin, Łukasz Smoliński, Anna Członkowka
Among patients with multiple sclerosis, discontinuing highly effective disease-modifying treatments can potentially lead to severe disease recurrence, especially cessation of natalizumab and fingolimod. Similar to fingolimod, siponimod is a sphingosine-1-phosphate receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph nodes. In the present case report, we describe a patient with MS who experienced substantial disease exacerbation after withdrawal from siponimod.
October 13, 2017: Neurologia i Neurochirurgia Polska
https://www.readbyqxmd.com/read/29108879/remyelination-modulators-in-multiple-sclerosis-patients
#9
Rabeah Al-Temaimi, Jehad AbuBaker, Irina Al-Khairi, Raed Alroughani
Multiple Sclerosis (MS) is a complex autoimmune neuro-inflammatory disorder characterized by persistent MS plaques in the central nervous system. Resolution of MS plaques is dependent on the remyelination competence of surviving oligodendrocytes and surrounding environment. Here, we assessed myelination modulators in a 100 MS patients against 77 healthy controls. Plasma fractions were used for the assessment of insulin growth factor binding protein1 (IGFBP1), brain-derived neurotrophic factor (BDNF), and lipocalin2 (LCN2) using a Luminex multiplex assay, whereas neurofilament light chain (NF-L) was assessed with an enzyme-linked immunosorbent assay...
November 8, 2017: Experimental and Molecular Pathology
https://www.readbyqxmd.com/read/29100032/extracorporeal-human-whole-blood-in-motion-as-a-tool-to-predict-first-infusion-reactions-and-mechanism-of-action-of-immunotherapeutics
#10
Erika A K Fletcher, Mohamed Eltahir, Frida Lindqvist, Jonas Rieth, Gunilla Törnqvist, Justyna Leja-Jarblad, Sara M Mangsbo
First infusion reactions along with severe anaphylactic responses can occur as a result of systemic administration of therapeutic antibodies. The underlying mechanisms by which monoclonal antibodies induce cytokine release syndrome (CRS) can involve direct agonistic effects via the drug target, or a combination of target-engagement along with innate receptor interactions. Despite the wide variety of pathways and cells that can play a role in CRS, many currently used assays are devoid of one or more components that must be present for these responses to occur...
October 27, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/29093064/assessing-association-of-comorbidities-with-treatment-choice-and-persistence-in-ms-a-real-life-multicenter-study
#11
Alice Laroni, Alessio Signori, Giorgia T Maniscalco, Roberta Lanzillo, Cinzia Valeria Russo, Eleonora Binello, Salvatore Lo Fermo, Annamaria Repice, Pietro Annovazzi, Simona Bonavita, Marinella Clerico, Damiano Baroncini, Luca Prosperini, Sara La Gioia, Silvia Rossi, Eleonora Cocco, Jessica Frau, Valentina Torri Clerici, Elisabetta Signoriello, Arianna Sartori, Ignazio Roberto Zarbo, Sarah Rasia, Cinzia Cordioli, Raffaella Cerqua, Alessia Di Sapio, Luigi Lavorgna, Simona Pontecorvo, Caterina Barrilà, Francesco Saccà, Barbara Frigeni, Sabrina Esposito, Domenico Ippolito, Fabio Gallo, Maria Pia Sormani
OBJECTIVE: To assess whether the presence of concomitant diseases at multiple sclerosis (MS) diagnosis is associated with the choice and the treatment persistence in an Italian MS cohort. METHODS: We included newly diagnosed patients (2010-2016) followed in 20 MS centers and collected demographic and clinical data. We evaluated baseline factors related to the presence of comorbidities and the association between comorbidities and the clinical course of MS and the time to the first treatment switch...
November 1, 2017: Neurology
https://www.readbyqxmd.com/read/29075657/impaired-t-cell-migration-to-the-cns-under-fingolimod-and-dimethyl-fumarate
#12
Amandine Mathias, Sylvain Perriot, Mathieu Canales, Claudia Blatti, Coline Gaubicher, Myriam Schluep, Britta Engelhardt, Renaud Du Pasquier
OBJECTIVE: To evaluate the long-term effects of treatments used in MS on the T-cell trafficking profile. METHODS: We enrolled 83 patients with MS under fingolimod (FTY), natalizumab (NTZ), dimethyl fumarate (DMF), or other disease-modifying treatments (DMTs). Blood was drawn before treatment onset and up to 36-48 months. The ex vivo expression of CNS-related integrins (α4β1 and αL subunit of LFA-1) and the gut-related integrin (α4β7) was assessed using flow cytometry on CD4(+) and CD8(+) T cells...
November 2017: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/29068484/the-clinical-utility-of-jc-virus-antibody-index-measurements-in-the-context-of-progressive-multifocal-leukoencephalopathy
#13
REVIEW
A Q Reuwer, M Heron, D van der Dussen, T Schneider-Hohendorf, J L Murk
In natalizumab-treated patients without previous immunosuppressive treatment, the JCV antibody index is used to stratify PML risk. A high index value indicates that the risk to develop PML is significantly elevated, although probably about 99% of patients with this index value will not develop PML. This minireview aimed to provide an overview of the basic virology and immunology relevant to understanding JCV infections in MS patients, with a focus on what is presently known about antibodies to JCV and how they could be of use to predict and diagnose PML...
November 2017: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/29055479/is-there-a-change-of-paradigm-towards-more-effective-treatment-early-in-the-course-of-apparent-high-risk-ms
#14
REVIEW
Óscar Fernández
BACKGROUND: Aggressive, highly active, or rapidly evolving severe relapsing-remitting multiple sclerosis (RRMS) is characterized by frequent relapses and active disease on magnetic resonance imaging, ultimately leading to a high risk for rapid disability accumulation. The treatment approach for high-risk patients is evolving into a model of individualized therapy in which early initiation of high-efficacy disease-modifying therapy (DMT), which I refer to as "early and strong" therapy, is viewed as a rational strategy to prevent the irreversible damage that occurs at disease onset and early in the disease course...
October 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29050389/towards-personalized-therapy-for-multiple-sclerosis-prediction-of-individual-treatment-response
#15
MULTICENTER STUDY
Tomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Marc Girard, Alexandre Prat, Pierre Duquette, Pierre Grammond, Patrizia Sola, Raymond Hupperts, Francois Grand'Maison, Eugenio Pucci, Cavit Boz, Raed Alroughani, Vincent Van Pesch, Jeannette Lechner-Scott, Murat Terzi, Roberto Bergamaschi, Gerardo Iuliano, Franco Granella, Daniele Spitaleri, Vahid Shaygannejad, Celia Oreja-Guevara, Mark Slee, Radek Ampapa, Freek Verheul, Pamela McCombe, Javier Olascoaga, Maria Pia Amato, Steve Vucic, Suzanne Hodgkinson, Cristina Ramo-Tello, Shlomo Flechter, Edgardo Cristiano, Csilla Rozsa, Fraser Moore, Jose Luis Sanchez-Menoyo, Maria Laura Saladino, Michael Barnett, Jan Hillert, Helmut Butzkueven
Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models of individual treatment response are lacking. Our aims were: (i) to develop predictive algorithms for individual treatment response using demographic, clinical and paraclinical predictors in patients with multiple sclerosis; and (ii) to evaluate accuracy, and internal and external validity of these algorithms. This study evaluated 27 demographic, clinical and paraclinical predictors of individual response to seven disease-modifying therapies in MSBase, a large global cohort study...
September 1, 2017: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/29034436/natalizumab-therapy-is-associated-with-changes-in-serum-jc-virus-antibody-indices-over-time
#16
John Peters, Eric Williamson
To examine changes in anti-JC Virus (JCV) index measurements over time in multiple sclerosis (MS) patients to better understand this test, which is used in assessing risk of progressive multifocal leukoencephalopathy (PML) with natalizumab. We aim to describe and compare seroconversion rates, variability of JCV antibody index values, and changes in index values over time between patients on natalizumab therapy and patients naïve to natalizumab. Anti-JCV index values are used to help decide whether to start, continue, or stop treatment...
October 16, 2017: Journal of Neurology
https://www.readbyqxmd.com/read/29023856/to-do-or-not-to-do-plasma-exchange-and-timing-of-steroid-administration-in-progressive-multifocal-leukoencephalopathy
#17
Cristina Scarpazza, Luca Prosperini, Nicola De Rossi, Lucia Moiola, Maria Pia Sormani, Simonetta Gerevini, Ruggero Capra
OBJECTIVE: To retrospectively analyze the effect of plasma exchange (PLEX; yes = PLEX(+) , no = PLEX(-) ) and steroids administration timing (prophylactically [proST] or therapeutically [therST]) on the longitudinal clinical course of patients with natalizumab-related progressive multifocal leukoencephalopathy (PML) and full-blown immune reconstitution inflammatory syndrome (PML-IRIS). METHODS: Clinical and radiological data of 42 Italian patients with PML were analyzed...
October 10, 2017: Annals of Neurology
https://www.readbyqxmd.com/read/28990853/response-to-letter-to-the-editor-on-the-paper-the-majority-of-natalizumab-treated-ms-patients-have-high-natalizumab-concentrations-at-time-of-re-dosing
#18
Zoé LE van Kempen, Theo Rispens, Joep Killestein
No abstract text is available yet for this article.
October 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28989935/pathologic-findings-of-chronic-pml-iris-in-a-patient-with-prolonged-pml-survival-following-natalizumab-treatment
#19
Mai Himedan, Sandra Camelo-Piragua, Elizabeth A Mills, Avneesh Gupta, Rany Aburashed, Yang Mao-Draayer
Immune reconstitution inflammatory syndrome (IRIS) is a common complication during treatment for natalizumab-associated progressive multifocal leukoencephalopathy (PML). Although severe IRIS can result in acute worsening of disability and is associated with poor prognosis, effective immune reconstitution may account for the high survival rate of this cohort of PML patients. We present pathological evidence of chronic IRIS 3.5 years after diagnosis with natalizumab-associated PML. Our case showed that the IRIS initially developed after plasma exchange therapy and resolved clinically and radiologically following a combination treatment with corticosteroids, maraviroc, and cidofovir...
July 2017: Journal of Investigative Medicine High Impact Case Reports
https://www.readbyqxmd.com/read/28975841/progressive-multifocal-leukoencephalopathy-and-monoclonal-antibodies-a-review
#20
Chandrashekar Bohra, Lubomir Sokol, Samir Dalia
Progressive multifocal leukoencephalopathy (PML) is a viral infection predominantly seen in patients with HIV infection. However, with the increased use of monoclonal antibodies (MAB) for various lymphoproliferative disorders, we are now seeing this infection in non-HIV patients on drugs such as natalizumab, rituximab, and so on. The aim of this article is to review the relationship between the occurrence of PML and MAB used in the treatment of hematological malignancies and autoimmune diseases. Review of articles from PubMed-indexed journals which study PML in relation to the use of MAB...
October 2017: Cancer Control: Journal of the Moffitt Cancer Center
keyword
keyword
27292
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"